Leukemia News and Research

RSS

Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.

New therapeutic target for patients with acute myeloid leukemia

According to a new study, targeting a pathway that is critical for the survival of some cases of acute myeloid leukemia could open up a new therapeutic route for patients.

3 May 2021

Small molecular changes can have dramatic impact on the CAR T cell function

When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn't respond, they went back to the drawing board to determine why.

23 Apr 2021

Researchers uncover a key genetic culprit in the development of acute lymphoblastic leukemia

Using a widely known field of mathematics designed mainly to study how digital and other forms of information are measured, stored and shared, scientists at Johns Hopkins Medicine and Johns Hopkins Kimmel Cancer Center say they have uncovered a likely key genetic culprit in the development of acute lymphoblastic leukemia (ALL).

21 Apr 2021

Study advances CAR T cell therapy targeted at cancer

Cancer immunotherapy involves the activation of cells in the patient’s own immune system to fight tumor cells.

19 Mar 2021

Study identifies molecular mechanism by which HSPCs recover after chemotherapy-induced injury

Chemotherapy has a damaging effect on hematopoietic stem and progenitor cells (HSPCs) in bone marrow. However, once chemotherapy ends, HSPCs regenerate, a process that has remained unknown--until now.

From Osaka University 8 Mar 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021

Cre-controlled CRISPR makes conditional gene inactivation more easier

To discover the function of a gene researchers turn it off and observe the consequences. Often genes have multiple functions that differ depending on a tissue and age.

24 Feb 2021

Research links blood-clotting protein with CNS B-cell lymphoma growth

In people with central nervous system (CNS) lymphoma, cancerous B cells--a type of white blood cell--accumulate to form tumors in the brain or spinal cord, often in close proximity to blood vessels.

18 Feb 2021

Hyperactive RANK protein could trigger autoimmune diseases

Autoimmune diseases, in which the body's own immune system attacks healthy tissue, can be life-threatening and can impact all organs.

3 Feb 2021

Yale scientists discover novel metabolic gatekeeper mechanism for leukemia

In a new study led by Yale Cancer Center, researchers have discovered a novel metabolic gatekeeper mechanism for leukemia. This mechanism depends on a molecule called PON2, which could lead to a new treatment for the disease. The findings were published online today in the Proceedings of the National Academy of Sciences (PNAS).

2 Feb 2021

Two enzymes drive pre-cancer stem cells into malignancy

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

From UC San Diego 27 Jan 2021

Drug-resistant, metastasis-causing cells produce exponentially growing tumors

The cover for issue 1 of Oncotarget features Figure 2, "Results in clinical trials," published in "Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer" by Blagoev, et al. which reported that most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered.

27 Jan 2021

New CAR T therapy could be more effective and less toxic against neuroblastoma

CAR T therapy has transformed the treatment for leukemia. Regrettably, the therapy is not effective enough to treat solid tumors, like neuroblastoma.

22 Jan 2021

Protein phosphatase inhibition could contribute to the treatment of cancer, other diseases

The abundant presence of an enzyme known as low molecular weight protein tyrosine phosphatase (LMWPTP) in tumor cells has long been considered an indicator of cancer aggressiveness and metastatic potential.

13 Jan 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Knocking out a protein known to stifle T cell activation on CAR T cells using the CRISPR/Cas9 technology enhanced the engineered T cells' ability to eliminate blood cancers, according to new preclinical data from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center.

8 Dec 2020

Researchers target pathogenic T cells that could lead to new immunotherapy treatments

According to a new study, a novel T cell genetically engineered by scientists from The University of Arizona Health Sciences can target and attack pathogenic T cells that are responsible for causing Type 1 diabetes. These latest findings may result in new immunotherapy therapies.

7 Dec 2020

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020

Scientists reveal health benefits of clonal hematopoiesis in allogeneic transplants

Clonal hematopoiesis (CH) is a recently identified condition in which mutations associated with blood cancers are detected in the blood of some healthy, usually older, individuals who don't have cancer. People with CH, while asymptomatic, have an elevated risk of developing blood cancers and other negative health outcomes, including heart attacks and strokes.

7 Dec 2020

CAR T cells display signs of efficacy against hard-to-treat pediatric cancer in phase 1 trial

A phase 1 trial involving 12 children with relapsed neuroblastoma - a hard-to-treat pediatric cancer - shows that anticancer CAR T cells displayed signs of efficacy against these tumors while avoiding damage to nerve tissue.

26 Nov 2020

Leukemia News and Research

New therapeutic target for patients with acute myeloid leukemia

Small molecular changes can have dramatic impact on the CAR T cell function

Researchers uncover a key genetic culprit in the development of acute lymphoblastic leukemia

Study advances CAR T cell therapy targeted at cancer

Study identifies molecular mechanism by which HSPCs recover after chemotherapy-induced injury

Engineered safety switch reduces CAR-T immunotherapy-related side effects

Cre-controlled CRISPR makes conditional gene inactivation more easier

Research links blood-clotting protein with CNS B-cell lymphoma growth

Hyperactive RANK protein could trigger autoimmune diseases

Yale scientists discover novel metabolic gatekeeper mechanism for leukemia

Two enzymes drive pre-cancer stem cells into malignancy

Drug-resistant, metastasis-causing cells produce exponentially growing tumors

New CAR T therapy could be more effective and less toxic against neuroblastoma

Protein phosphatase inhibition could contribute to the treatment of cancer, other diseases

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

Mice infused with CD5-deleted CAR T cells showed significant reduction in tumor size

Researchers target pathogenic T cells that could lead to new immunotherapy treatments

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

Scientists reveal health benefits of clonal hematopoiesis in allogeneic transplants

CAR T cells display signs of efficacy against hard-to-treat pediatric cancer in phase 1 trial

Quorum Bio: Where Synthetic Biology Meets Sustainable Farming

Diagnostic Biochips: Pioneering Brain Research Tools for the Future

Commercializing Innovation in a Life Sciences Ecosystem

Latest in Genomics